

Press release

Gradientech responds to call for new diagnostic approaches to combat antimicrobial resistance at AMR Conference in Berlin

Uppsala, Sweden, March 18, 2019. Speaking at the Novel Antimicrobials and AMR Diagnostics Conference in Berlin, Gradientech, developer of the QuickMIC™ rapid IVD system for antibiotic susceptibility testing (AST), stressed the importance of adopting new diagnostic approaches in the fight against antimicrobial resistance.

Antibiotic resistance is one of the biggest threats to global health today. Its impact is perhaps seen most clearly in the continuing rise in deaths from infections due to bacteria resistant to antibiotics – at least 33,000 annually in Europe alone.

“The World Health Organization has already called for a new generation of rapid microbiology tests to determine which antibiotics an infected patient should be treated with to reduce misuse and overuse of antibiotics and limit the spread of resistance,” says Sara Thorslund, CEO of Gradientech. “We foresee that our IVD QuickMIC system, which is in final development, will make a real difference by diagnosing bacterial resistance in patients with suspected sepsis in as short as 2 hours based on bacterial growth.”

At the AMR conference, Gradientech was participating in a special session on diagnostics chaired by Dr Till Bachmann from the University of Edinburgh, and member of the JPIAMR (Joint Programming Initiative on Antimicrobial Resistance) SAB, who added: “Reducing over and inappropriate use of antibiotics remains a major challenge. New diagnostic approaches are urgently required, and I welcome the initiatives of companies such as Gradientech and the other panellists here in Berlin.”

For more information, please contact:

Sara Thorslund, CEO, Tel +46 (0) 18 418 6700

Email: sara.thorslund@gradientech.se

TO THE EDITORS

About Gradientech AB

Gradientech is a Swedish biotech and diagnostic company focusing on innovative microfluidic product development. We provide systems for high-quality analysis of cell behavior in response to gradients of biomolecules. Gradientech is currently developing QuickMIC™, a precision system for ultra-rapid antibiotic susceptibility testing. QuickMIC is designed to offer personalized treatment options for sepsis patients, thereby contributing to increased survival, reduced healthcare costs and lower antibiotic resistance.

www.gradientech.se

About the Novel Antimicrobials and AMR Diagnostics Conference in Berlin

The aim is to establish the Berlin Conference as the one-stop-shop and meeting place in Europe for all AMR relevant stakeholders in industry, finance, policy and application-oriented science. <https://amr-conference.com/about/>